EO2002 low dose

Phase 1Biologic

EEmmecell

EO2002 low dose is one of 6 biologic programs targeting Corneal Edema. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal EdemaActive, not recruiting

Corneal EdemaPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Corneal Edema

#DrugCompanyPhaseTrials

Kenalog

BBassett Healthcare

Approved

—2

Decadron

AAspen Global Incorporated

Alphagan

Rhopressa

2 5

EO2002 low dose

EEmmecell

Phase 1

1 6

EO2002

AAsociación para Evitar la Ceguera en México

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Edema1 trial

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Completed·EEmmecell·Phase 1·NCT04894110·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EO2002 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EO2002 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EO2002 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emmecell company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: EEmmecell

EO2002 low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Corneal Edema1 trial

References

Drug Info

Quick Facts

Related News